Adams Laboratories

Adams Laboratories, later known as Adams Respiratory Therapeutics, was a specialty pharmaceutical company dedicated to the development and commercialization of respiratory health products. The company achieved significant commercial success with the launch of Mucinex, the first FDA-approved extended-release guaifenesin product for treating chest congestion. By strategically navigating the FDA's regulatory framework to remove unapproved generic alternatives, Adams established a dominant market position for its core brands, which also included the long-acting cough suppressant Delsym. In 2008, the company was acquired by Reckitt Benckiser for approximately $2.3 billion, integrating its respiratory franchise into a global consumer healthcare portfolio. The company's legacy continues through its market-leading brands, which remain cornerstones of the over-the-counter respiratory market.